Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
After-Hours Stock Movers 01/05: (CNAT) (ICON) (BLUE) Higher; (EPZM) (CEMP) (OTIC) Lower (more...)
January 5, 2016 6:12 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) 15% HIGHER; three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences between treatment and placebo groups in baseline Model for End-stage Liver Disease (MELD)1 score and disease etiology as specified in the trial statistical analysis plan.
Epizyme, Inc. (NASDAQ: EPZM) 10% LOWER; announced that it intends to... More
Conatus Pharmaceuticals (CNAT) Resumes Trading; Shares Up 10%
January 5, 2016 4:38 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month, double-blind, placebo-controlled stage... More
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ET
January 5, 2016 4:11 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 4.35 PM ET
... MoreConatus Pharmaceuticals (CNAT) Emricasan Phase 2 Liver Cirrhosis Trial Shows Statistically Significant Reduction in cCK18
January 5, 2016 4:07 PM ESTConatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced that the three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences... More
Conatus Pharmaceuticals (CNAT) halted, news pending
January 5, 2016 4:01 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) halted, news pending
... More